- Colorectal (CRC) is the worldwide third leading cancer in incidence and mortality, according the WHO.
- European guidelines recommend CRC prevention based on screening the population risk (all 50-75-years-old population).
- The current organized screening programs use Immunological Fecal occult blood Test (FIT) base on detecting blood in feces. But, because blood is not a specific marker of CRC, using FIT in its maximum sensitivity implies an high rate of false positive and induce a large amount of unnecessary colonoscopies.
- Specific non-invasive screening tools focused on detection at early stages become a keystone in order to prevent CRC.
RAID-CRC is a patented non-invasive system that complements FIT screening with determination CRC microbiological signature in fecal sample.
- Microbiologial signature defined in 80 intestinal biopsies with CRC and normal colonoscopy. The identification of these bacteria in adherent intestinal mucosa allows us to avoid their vulnerability to dietary changes in different populations. Clinical validation with the University Hospital Dr. Josep Trueta.
- Multi-centre study with 450 patients with symptoms pointing to CRC who had had a colonoscopy at five Catalan hospitals that are leaders in oncology: University Hospital Dr Josep Trueta, Bellvitge University Hospital, Catalan Institute of Oncology, Healthcare Institute (IAS) and the Hospital Consortium of Vic.
In 2018 we aim to perform a clinical validation in German screening population and launch RAID-CRC to the market in 2019 with total financial needs of 4 million euros.
Fecha: del 14 al 16 de marzo de 2018 Lugar: Hotel Meliá Castilla ...
GoodGut has presented positive results for the RAID-CRC test which will improve early detection ...
Today is World Inflammatory Bowel Disease (IBD) Day; IBD is a set of ...
La segona edició de l’esdeveniment “La Girona de les Solucions”, que organitzen En ...